1. Home
  2. CIVI vs CELC Comparison

CIVI vs CELC Comparison

Compare CIVI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civitas Resources Inc.

CIVI

Civitas Resources Inc.

HOLD

Current Price

$27.19

Market Cap

2.6B

Sector

Energy

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$102.36

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIVI
CELC
Founded
1999
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
3.1B
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
CIVI
CELC
Price
$27.19
$102.36
Analyst Decision
Hold
Strong Buy
Analyst Count
13
8
Target Price
$40.80
$100.13
AVG Volume (30 Days)
1.3M
858.0K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
7.41%
N/A
EPS Growth
N/A
N/A
EPS
6.86
N/A
Revenue
$4,711,808,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.93
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.79
$7.58
52 Week High
$55.35
$112.64

Technical Indicators

Market Signals
Indicator
CIVI
CELC
Relative Strength Index (RSI) 41.99 64.34
Support Level $26.95 $97.27
Resistance Level $28.56 $112.64
Average True Range (ATR) 1.04 5.11
MACD -0.28 -1.32
Stochastic Oscillator 14.83 48.78

Price Performance

Historical Comparison
CIVI
CELC

About CIVI Civitas Resources Inc.

Civitas Resources Inc is an independent exploration and production company engaged in the acquisition, development, and production of oil and associated liquids-rich natural gas in the Rocky Mountain region, in the Denver-Julesburg Basin of Colorado - DJ Basin. The company's operations are focused on developing the horizontal Niobrara and Codell formations that have a low-cost structure, mature infrastructure, production efficiencies, multiple producing horizons, multiple service providers, established reserves, and prospective drilling opportunities.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: